Subscribe to RSS
DOI: 10.1055/a-1985-1728
Lassafieber
Lassafieber gehört zu den viralen hämorrhagischen Fiebererkrankungen (wie auch Ebola-, Marburg-, oder Krim-Kongo-Fieber), die als Infektionskrankheiten mit hohem Krankheitswert (High Consequence Infectious Diseases, HCID) gelten ([Tab. 1]). Mit dem Auftreten dieser Erreger muss durch Einschleppung aus Endemiegebieten, im Rahmen von bioterroristischen Aktivitäten oder bei Laborunfällen gerechnet werden.
|
Durch direkten Kontakt übertragbare HCID |
Aerogen übertragene HCID |
|
Argentinisches hämorrhagisches Fieber (Junin-Virus) |
Andenvirus-Infektion (Orthohantavirus) |
|
Bolivianisches hämorrhagisches Fieber (Machupo-Virus) |
Aviäre Influenza A/H7N9 und H5N1 |
|
Hämorrhagisches Krim-Kongo-Fieber (CCHF) |
Aviäre Influenza A/H5N6 und H7N7 |
|
Ebolavirus-Krankheit (EVD) |
Middle East Respiratory Syndrome (MERS) |
|
Lassafieber |
Affenpocken |
|
Lujo-Virus-Krankheit |
Nipah-Virus-Infektion |
|
Marburgvirus-Krankheit (MVD) |
Lungenpest (Yersinia pestis) |
|
Schweres Fieber mit Thrombozytopenie-Syndrom (SFTS) |
Schweres akutes Atemwegssyndrom (SARS-CoV-1) |
|
Milzbrand (Bacillus anthracis) |
Publication History
Article published online:
09 January 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Kalbitz S, Kellner N, Macholz M. et al. Erkrankungen durch hochpathogene Erreger – Teil 1. Krankenhaushygiene up2date 2022; 17: 367-386
- 2 Agbonlahor DE, Erah E, Agba IM. et al. Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria. J Vector Borne Dis 2017; 54: 146-150
- 3 Robert-Koch-Institut (RKI). Ratgeber Lassafieber. . Accessed November 08, 2022 at: https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Lassa-Fieber.html;jsessionid=30E50BD21C978704F510E602BB55A14D.internet122?nn=2386228
- 4 Forni D, Pontremoli C, Pozzoli U. et al. Ancient evolution of mammarenaviruses: adaption via changes in the L protein and no evidence for host- virus codivergence. Genome Biol Evol 2018; 10: 863-874
- 5 Fichet-Calvet E, Rogers DJ. Risk Maps of Lassa Fever in West Africa. PLoS Negl Trop Dis 2009; 3: e388
- 6 Frame JD, Baldwin Jr JM, Gocke DJ. et al. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970; 19: 670-676
- 7 Centers for Disease Control and Prevention (CDC). Lassa Fever.. Accessed November 08, 2022 at: https://www.cdc.gov/vhf/lassa/index.html
- 8 Ibukun FI. Inter-Lineage variation of Lassa virus glycoprotein epitopes: a challenge to Lassa virus vaccine development. Viruses 2020; 12: 386
- 9 Murphy HL, Ly H. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments. Virulence 2021; 12: 2989-3014
- 10 Fisher-Hoch SP, Tomori O, Nasisi A. et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995; 311: 857-859
- 11 Johnson KM, McCormick JB, Webb PA. et al. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 1987; 155: 456-464
- 12 McCormick JB, King IJ, Webb PA. et al. Lassa Fever. New Engl J Med 1986; 314: 20-26
- 13 Mateer EJ, Huang C, Shehu NY. et al. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl Trop Dis 2018; 12: e0006187
- 14 UK Health Security Agency. Lassa fever: origins, reservoirs, transmission and guidelines. . Accessed November 08, 2022 at: https://www.gov.uk/guidance/lassa-fever-origins-reservoirs-transmission-and-guidelines#symptoms
- 15 Salam AP, Duvignaud A, Jaspard M. et al. Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis 2022; 16: e0010289
- 16 Raabe VN, Kann G, Ribner BS. et al. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clin Infect Dis 2017; 65: 855-859
- 17 Fischer RJ, Purushotham JN, van Doremalen N. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines 2021; 6: 32